These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 16426921)
1. C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu. Diallo R; Rody A; Jackisch C; Ting E; Schaefer KL; Kissler S; Karn T; Geddert H; Engels K; Kaufmann M; Gabbert HE; Shroyer KR; Poremba C Hum Pathol; 2006 Feb; 37(2):205-11. PubMed ID: 16426921 [TBL] [Abstract][Full Text] [Related]
2. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Hussein MR; Abd-Elwahed SR; Abdulwahed AR Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077 [TBL] [Abstract][Full Text] [Related]
3. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Steinman S; Wang J; Bourne P; Yang Q; Tang P Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367 [TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast. Rody A; Diallo R; Poremba C; Speich R; Wuelfing P; Kissler S; Solbach C; Kiesel L; Jackisch C Oncol Rep; 2004 Oct; 12(4):695-9. PubMed ID: 15375487 [TBL] [Abstract][Full Text] [Related]
5. Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. Claus EB; Chu P; Howe CL; Davison TL; Stern DF; Carter D; DiGiovanna MP Exp Mol Pathol; 2001 Jun; 70(3):303-16. PubMed ID: 11418009 [TBL] [Abstract][Full Text] [Related]
6. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women. Rodrigues NA; Dillon D; Carter D; Parisot N; Haffty BG Cancer; 2003 Mar; 97(6):1393-403. PubMed ID: 12627502 [TBL] [Abstract][Full Text] [Related]
7. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Moinfar F; Okcu M; Tsybrovskyy O; Regitnig P; Lax SF; Weybora W; Ratschek M; Tavassoli FA; Denk H Cancer; 2003 Aug; 98(4):703-11. PubMed ID: 12910513 [TBL] [Abstract][Full Text] [Related]
8. Expression patterns of ER-alpha, PR, HER-2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ. Tang P; Wang X; Schiffhauer L; Wang J; Bourne P; Yang Q; Quinn A; Hajdu S Ann Clin Lab Sci; 2006; 36(2):137-43. PubMed ID: 16682508 [TBL] [Abstract][Full Text] [Related]
9. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast. Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076 [TBL] [Abstract][Full Text] [Related]
10. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone. Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090 [TBL] [Abstract][Full Text] [Related]
11. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183 [TBL] [Abstract][Full Text] [Related]
12. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Wärnberg F; Nordgren H; Bergkvist L; Holmberg L Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839 [TBL] [Abstract][Full Text] [Related]
13. [Clinicopathologic features and treatment of ductal carcinoma in situ of the breast]. Zhou L; Wang Y; Song X; Du JW; Pei F; Huang LP; Wang WY; Liu ZB; Pan RQ Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3035-8. PubMed ID: 16324401 [TBL] [Abstract][Full Text] [Related]
14. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. Ottesen GL APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968 [TBL] [Abstract][Full Text] [Related]
15. Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Hoque A; Sneige N; Sahin AA; Menter DG; Bacus JW; Hortobagyi GN; Lippman SM Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):587-90. PubMed ID: 12050101 [TBL] [Abstract][Full Text] [Related]
16. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study. Wilbur DC; Barrows GH Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877 [TBL] [Abstract][Full Text] [Related]
17. Expression of C-KIT and HER-2 tyrosine kinase receptors in poor-prognosis breast cancer. Palmu S; Söderström KO; Quazi K; Isola J; Salminen E Anticancer Res; 2002; 22(1A):411-4. PubMed ID: 12017324 [TBL] [Abstract][Full Text] [Related]
18. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression. Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840 [TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Lodato RF; Maguire HC; Greene MI; Weiner DB; LiVolsi VA Mod Pathol; 1990 Jul; 3(4):449-54. PubMed ID: 2170971 [TBL] [Abstract][Full Text] [Related]
20. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast. Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]